

Notification: eviQ Medical Oncology – breast adjuvant and neoadjuvant website navigation and protocols – 31 August 2022

Medical oncology breast adjuvant and neoadjuvant protocols are now combined under the one category heading on the [eviQ website](#).

In order to rationalise duplicate protocols across different indications and allow for more efficient maintenance of eviQ content, new multi-indication adjuvant/neoadjuvant breast protocols have been developed to replace some existing single indication protocols as shown in the table below.

These changes have been completed in consultation with the eviQ Medical Oncology reference committee.

The previous single indication protocol ID numbers still exist in the eviQ system, and these now redirect to the corresponding new multi-indication protocols.

Note the previous single indication protocol ID numbers are no longer searchable via the eviQ search bar. However, they can be accessed by navigating via the direct URL ie https://www.eviq.org.au/p/*ID number* and this will redirect to the new/updated multi-indication protocol e.g. <https://www.eviq.org.au/p/134> will redirect to ID 4102.

It is clearly documented in the History section of the new multi-indication adjuvant/neoadjuvant breast protocols, which previous single indication protocols it replaces.

New/updated multi-indication adjuvant/neoadjuvant breast protocols	Previous single indication protocols (now redirected)
ID 4102 Breast adjuvant/neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense	ID 134 Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense
	ID 1869 Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense
ID 4103 Breast adjuvant/neoadjuvant PACLitaxel weekly	ID 132 Breast adjuvant PACLitaxel weekly
	ID 3377 Breast neoadjuvant PACLitaxel weekly (part 2)
ID 4104 Breast adjuvant/neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly	ID 128 Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly
	ID 72 Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly
ID 4113 Breast adjuvant/neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly followed by PACLitaxel weekly overview	ID 1605 Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLitaxel weekly overview
	ID 3376 Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLitaxel overview
ID 4114 Breast adjuvant/neoadjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide)	ID 13 Breast adjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide)
	ID 1295 Breast neoadjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide)

ID 4115 Breast adjuvant/neoadjuvant trastuzumab three weekly	ID 127 Breast adjuvant trastuzumab three weekly
	ID 1323 Breast neoadjuvant trastuzumab three weekly
ID 4133 Breast adjuvant EC (epirubicin and CYCLOPHOSPHamide)	ID 683 Breast adjuvant EC (epirubicin and CYCLOPHOSPHamide)
	ID 3914 Breast adjuvant EC (epirubicin and CYCLOPHOSPHamide) (part 1 of EC-D)
ID 4134 Breast adjuvant/neoadjuvant DOCEtaxel	ID 3915 Breast adjuvant D (DOCEtaxel) (part 2 of EC-D)
	ID 1325 Breast neoadjuvant DOCEtaxel three weekly (part 2)
ID 19 Breast adjuvant anastrozole	ID 20 Breast adjuvant anastrozole (early switch)
ID 30 Breast adjuvant letrozole	ID 31 Breast adjuvant letrozole (late switch)